

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) ~~A method to inhibit activation of an inflammatory cell which interacts with a columnar epithelium~~ A method for treating or preventing a disease or condition associated with columnar epithelial inflammation in a subject comprising,
administering to a subject an effective amount of a lipoxin A₄ compound.

2. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the kidney.

3. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the stomach.

4. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the liver.

5. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the thyroid.

6. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the trachea.

7. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the lung.

8. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the gall bladder.

9. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the urinary bladder.

10. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the bile duct.

11. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the pancreatic duct.


12. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the testicle.

13. (Previously Presented) The method of claim 1, wherein the columnar epithelium is an epithelium of the intestine.

14. (Previously Presented) The method of claim 1, wherein the lipoxin compound is an analog of natural lipoxin A₄.


15. (Previously Presented) The method of claim 14, wherein the analog of natural lipoxin A₄ has a longer half-life than natural lipoxin A₄.

16. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

17. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

18. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

19. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

20. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

21. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

22. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

23. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

24. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

25. (Previously Presented) The method of claim 15, wherein the lipoxin analog is




where R' is H or CH₃.

26. (Previously Presented) The method of claim 15, wherein the lipoxin analog is



where R' is H or CH₃.

27. (Previously Presented) The method of claim 15, wherein the lipoxin analog is



where R' is H or CH₃.

Claim 28 (Canceled).